For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .
Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer
Factors related to the prevalence , prediction , and course of anticipatory nausea ( AN ) in women ( n = 77 ) receiving adjuvant chemotherapy for breast cancer were examined . Using a prospect i ve longitudinal research design , patients were interviewed both before and after each chemotherapy infusion . Fifty‐seven percent of the patients developed AN . These patients were characterized by more severe gastrointestinal side effects following the initial infusion and greater expectations for experiencing chemotherapy‐related nausea . A more rapid development of AN was related to a history of experiencing nausea across a greater variety of situations , higher IV drug doses , and less infusion‐related anxiety at the initial infusion . Although AN occurred intermittently across treatment sessions , severity was constant . Results provided strong support for the hypothesis that classical conditioning processes are instrumental in AN acquisition . The role of anxiety in the development of AN is considered as are clinical implication s for the prevention of AN and recommendations for future research
For persons receiving chemotherapy of high emetic risk , there is no group of patients for whom agents of lower therapeutic index are appropriate first-choice antiemetics .
In all patients receiving cisplatin and all other agents of high emetic risk , the two-drug combination of dexamethasone and aprepitant is recommended for the prevention of delayed emesis .
The Up date Committee no longer recommends the combination of a 5-HT3 serotonin receptor antagonist and dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk .
PURPOSE To up date the 1999 American Society of Clinical Oncology guideline for antiemetics in oncology .